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Background: The sensitivity of a mammography program is normally evaluated by comparing the interval cancer
rate to the expected breast cancer incidence without screening, i.e. the proportional interval cancer rate (PICR).
The expected breast cancer incidence in absence of screening is, however, difficult to estimate when a
program has been running for some time. As an alternative to the PICR we propose the interval cancer ratio
ICR ¼ interval cancersinterval cancers þ screen detected cancers
 
. We validated this simple measure by comparing it with the
traditionally used PICR.
Method: We undertook a systematic review and included studies: 1) covering a service screening program,
2) women aged 50-69 years, 3) observed data, 4) interval cancers, women screened, or interval cancer rate, screen
detected cases, or screen detection rate, and 5) estimated breast cancer incidence rate of background population.
This resulted in 5 papers describing 12 mammography screening programs.
Results: Covering initial screens only, the ICR varied from 0.10 to 0.28 while the PICR varied from 0.22 to 0.51. For
subsequent screens only, the ICR varied from 0.22 to 0.37 and the PICR from 0.28 to 0.51. There was a strong
positive correlation between the ICR and the PICR for initial screens (r = 0.81), but less so for subsequent screens
(r = 0.65).
Conclusion: This alternate measure seems to capture the burden of interval cancers just as well as the traditional
PICR, without need for the increasingly difficult estimation of background incidence, making it a more accessible
tool when evaluating mammography screening program performance.
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Mammography screening is intended to reduce breast
cancer mortality by detecting the breast cancer cases at
an earlier stage. A high sensitivity is needed for a mam-
mography screening program to fulfil its purpose. This
means the program should not have too many interval
cancers, i.e. cancers that appear clinically after a negative
screening result and before the next scheduled screen. A
screening program in a population with a high breast
cancer incidence can have a high interval cancer rate and* Correspondence: suban@sund.ku.dk
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unless otherwise stated.still have as protective an effect on breast cancer mortal-
ity as a screening program with a low interval cancer rate
running in a population with a low breast cancer
incidence. The sensitivity of a mammography screening
program is therefore normally evaluated by comparing
the interval cancer rate to the expected breast cancer
incidence without screening, i.e. the PICR [1]. In order
to compare sensitivity across screening programs, the
European guidelines provide acceptable and desirable
values for this measure. However, over time the difficul-
ties in estimating the expected background incidence
makes such comparisons increasingly unreliable.
The expected breast cancer incidence in absence of
screening, or background incidence, is difficult to approxi-
mate, as the introduction of a screening program makes it
difficult to find an unscreened, comparable populationral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain









Andersen et al. BMC Cancer 2014, 14:782 Page 2 of 8
http://www.biomedcentral.com/1471-2407/14/782group. As the breast cancer incidence has changed over
time [2], it will, some years after introducing of screening,
no longer be meaningful to estimate the expected breast
cancer incidence without screening from the breast cancer
incidence prior to the screening.
The aim of this article is to propose and validate an alterna-
tive performance indicator for the burden of interval cancers
in an organized mammography screening program. We aim
to validate this proposed measure by comparing with the
PICR from studies of service screening programs for women
aged 50-69. Zorzi et al. [3] have previously proposed that for a
given subsequent screening round, PICR is substituted
by 1− SDin regular attendersSDin regular attenders þ ICin regular attenders . We propose to
use the even simpler 1− SDin all participantsSDin all participants þ ICin all participants
¼ ICin all participantsICin participants þ SDin participants and to use this measure also
for the initial screening round.96 selected 3203 discarded
5 fulﬁlling all 
criterias
Figure 1 Flow diagram of selection of papers.Methods
Search strategy
We performed a PubMed search using Major MeSH terms
with the restriction of the words “mammography” or
“screening” required in the abstracts where abstracts were
available, in the title where abstracts were not available,
and finally in free texts, see Additional file 1. We did this
search in March 2012, and it was limited to publications in
English. This search resulted in 3299 matches. Among
these matches, relevant studies were identified in a two-
step search. First, two independent researchers, SBA &
SHN, reviewed the titles and abstracts of the 3299 papers.
This sorting resulted in 96 papers for further consideration.
Second, we selected studies: 1) covering a service screening
program, 2) including women aged 50-69 years, 3) report-
ing observed data (paper based on modeling only were
excluded), 4) reporting number of screen detected cancers
or screen detection rates and number of screened women
and two of these: number of interval cancers, interval can-
cer rate or number of screened women and 5) reporting
estimated breast cancer incidence rate of the background
population in the absence of screening. Third, in case con-
sensus was not obtained, a third researcher, EL, partici-
pated in the decision. This resulted in inclusion of 5 papers
[4-8] describing 12 different screening programs, to be in-
cluded in this review, Figure 1.Definitions
Screen detected cancers
A primary breast cancer found at scheduled screening
examination. Some centers allowed a so-called early re-
call (or intermediate mammography) prescribed for
diagnostic reasons 1 year after the screening test. Cases
detected at early recall are calculated as SD cancers.Interval cancer
A primary breast cancer diagnosed in a woman, after a
screening test negative for malignancy. The breast can-
cer should either be diagnosed before the next invitation
to screening, or within a time period equal to the
screening interval in case the woman has reached the
upper age limit for screening or for other reasons does
not receive more invitations.Proportional interval cancer rate (PICR)
Interval cancer rate as a proportion of the underlying,
expected, breast cancer incidence rate in the absence of
screening: interval cancer rateexpected background incidence . This is the classic
epidemiology performance indicator [9] as used in the
EU Guidelines [1].Interval cancer ratio (ICR)
Interval cancer as proportion all cancers: ICR ¼
interval cancers
interval cancers þ screen detected cancers . This is the measure we
propose as an alternative performance indicator.
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From each paper we extracted: Information on number
of screened women and number of screen detected
cancers or screen detection rate, the expected back-
ground annual incidence rate per 10,000 and number
of interval cancer cases. If not provided, we calculated
interval cancer cases per 10,000 screen negative
women (this being number of women screened minus
number of screen detected cases). Finally we calculated
PICR ¼ Interval cancers per 10;000Background annual incidence rate per 10;000 and ICR
¼ Interval cancersInterval cancers þ screened detected cases . In the Veneto re-
gion study the interval cancers were identified by link-
age to the regional hospital discharge records. For all
other studies interval cancers were identified by link-
age to the regional/national cancer register, which all
are regarded as complete.
Initial versus subsequent screens
The number of screen detected cases is higher in initial
screens than in subsequent screens. Therefore the ICR
will be lower in initial screens than in subsequent
screens. When comparing interval cancer ratios one
therefore has to distinguish between initial screens and
subsequent screens. All studies had a screening interval
of 2 years, except Marseille where the screening interval
was 3 years.
Analysis
Pearson’s correlation coefficient and best-fit straight line
was calculated using Microsoft Office Excel 2007.
Results
The ICR in studies of initial screens varied from 0.10 to
0.28 while the PICR varied from 0.22 to 0.51 in the same
studies (Table 1). In studies of subsequent screens the
ICR varied from 0.22 to 0.37 with the PICR varying from
0.28 to 0.61 (Table 2). Four studies reported on mixed
initial and subsequent screens. The Italian study from
the Veneto Region with a majority of initial screens, had
an ICR of 0.18, and a PICR of 0.29. The studies from
Copenhagen, Denmark, Funen, Denmark and Pirkan-
maa, Finland with a majority of subsequent screens, had
an ICR of 0.25-0.34 and a PICR of 0.40-0.61.
All studies estimated the expected background inci-
dence by the observed incidence just before the mam-
mography screening program started. With the breast
cancer incidence increasing over time [2], this estimated
background incidence will consequently increasingly
underestimate the true background incidence.
The Norwegian NBCSP study estimated the back-
ground incidence by the observed incidence in women
aged 50-69 years before screening started. This will
underestimate the expected incidence, since the observedinterval cancer rate will derive from women on average
being two years older.
The Italian Veneto Region study is based on invasive
cancers only, whereas all other studies are based on in-
vasive + ductal carcinoma in situ (DCIS). Since DCIS is
far more common among screen-detected cancers calcu-
lations excluding DCIS will increase the ICR more than
the PICR.
The correlation between ICR and PICR was r = 0.76
for initial screens (Figure 2), and r = 0.58 for subsequent
screens (Figure 3).
When comparing PICRs across screening programs, dif-
ferences can reflect true differences in interval cancer
rates; differences in methods for estimating the expected
background incidence; or differences in the time trend of
breast cancer incidence. By using the ICR, instead of esti-
mating the PICR, the uncertainty introduced by estimat-
ing the expected background incidence is avoided. Hence,
the ICR is potentially a better performance indicator as no
estimation is needed. The question is, however, whether
this suggested simple performance indicator captures
interval cancer burden as well as the old measure.
As seen in Figure 2 there is a high positive correlation
(r = 0.76) between the two measures in initial screens.
Outliers are Stockholm, Norway, Copenhagen, Marseille,
Strasbourg and the Italian Veneto Region. Stockholm
and Norway had quite extensive opportunistic screening
before the service screening program started [7,10]. One
could therefore argue that the data from these locations
did not represent 100% initial screens but were probably
more in line with the Veneto Region program, which
had 73% initial screens. Since the ICR will be higher for
subsequent screens, it was not surprising that the
Stockholm, Norway and Veneto Region programs had
relatively high ICR for initial screens. The high ICR for
the Veneto Region was also a consequence of including
only invasive cancers.
The relationship between the ICR and PICR for studies
with primarily subsequent screens (seen in Figure 3)
showed a strong positive correlation (r = 0.58). Data from
Turin and Florence are based on small numbers (25 and
28 interval cancers respectively), and excluding these two
programs gave a stronger correlation (r = 0.68).
Discussion
When the expected background incidence is calculated
based on the incidence of the general population, the
actually screened population could have a different ex-
pected background incidence; especially if the attendance
rate is low. Marseille had an attendance rate of 43% and
had a 3 year screening interval until 2001. Strasbourg
had no active invitation for the first screen, implying that
the incidence of the screened population could be differ-
ent from that of the general population. If we excluded







































1991-‘93 50-69 30,362 360 52 100 118.6 17.3 25.4 0.34 0.13 (0.10-0.16)
Njor et al. [6] Funen,
Denmark










1996-‘97 50-69 126,779 852 207 100 67.2 16.4 20.0 0.41 0.20 (0.18-0.22)
Hofvind
et al. [4]










1989-‘97 50-65 63,235 328 129 100 51.9 20.5 22.6 0.45 0.28 (0.24-0.32)
Törnberg
et al. [7]
Florence, Italy 1990-‘94 50-69 35,754 325 47 100 90.9 13.3 22.2 0.30 0.13 (0.10-0.16)
Törnberg
et al. [7]





1999-‘02 50-69 94,874d 683 154 73 72.0 16.3 27.8 0.29 0.18 (0.15-0.21)
Törnberg
et al. [7]
Navarra, Spain 1990-‘96 45-65 40,665 256 29 100 63.0 7.2 16.2 0.22 0.10 (0.07-0.13)
aOnly 367,428 prevalent screens from a total of 467,343 women had 2 years of follow-up.
bAlthough the age group targeted in Turin is 50-69 years, during the period of the study, invitations were restricted to women aged 50-59. A few women had the test shortly after they turned 60.
cBased on the ages 50-64.

























































1993-‘95 50-69 26,063 163 53 18 62.5 20.5 25.4 0.40 0.25 (0.19-0.31)
Njor et al. [6] Funen,
Denmark

























1989-‘97 50-65 104,951 390 230 0 37.2 22.0 22.6 0.49 0.37 (0.33-0.41)
Törnberg
et al.[7]
Florence, Italy 1990-‘94 50-69 13,394 54 28 0 40.3 21.0 22.2 0.47 0.34 (0.24-0.44)
Törnberg
et al.[7]





1990-‘96 45-65 85,653 268 77 0 31.3 9.0 16.2 0.28 0.22 (0.18-0.26)
aOnly 336,323 prevalent screens from a total of 467,343 women had 2 years of follow-up.
bbased on the ages 50-59 years.
cAlthough the age group targeted in Turin is 50-69 years, during the period of the study, invitations were restricted to women aged 50-59. A few women had the test shortly after they turned 60. and all women
invited for the first time in their 50s received their subsequent invitations even after they turned 60.
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Figure 2 Relationship between total IC-rate/BG-rate (PICR) and number of IC/number of total cancers (ICR), primarily initial screens.
NB. Veneto Region is the only program with mixed initial and subsequent screens. The diagonal line is the best-fit line for the observations.
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http://www.biomedcentral.com/1471-2407/14/782Marseille and Strasbourg from the comparison, we got a
correlation of r = 0.73 for initial screens. If we for subse-
quent screens excluded Turin, Florence, Marseille and
Strasbourg we got a correlation of r = 0.73.
In randomized controlled studies (RCTs) the expected
background incidence is the incidence found in the con-
trol group. PICR can therefore be calculated with great
confidence in RCTs. We found information on interval
cancers and screen detected cancers in both arms of the
Gothenburg Breast Screening Trial [11] and the Swedish
two-county trial [12]. We could only find information on





















Figure 3 Relationship between total IC-rate/BG-rate (PICR) and numb
screens. NB. Pirkanmaa is the only program with mixed subsequent and inentire period wherefore the incidence in the control arm
included one screening. We did neither find information
stratified into initial and subsequent screenings. The
value of ICR and PICR are therefore not entirely compar-
able with the values in the studies included in this review.
Based on the results from Gothenburg Breast Screening
Trial we calculated ICR = 0.21 and PICR = 0.20. From the
results in the two-county trial we calculated ICR = 0.27
and PICR = 0.21. Although the results are not completely
comparable the ICR and PICR values from these two
RCTs are very close to the line showing the connection
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itial screens.
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pare interval cancer rates across screening programs,
since an estimation of an expected background inci-
dence is not needed. Especially when controlling for
other differences between the programs, we see a high
correlation between the PICR and the ICR. It is there-
fore possible to get a reasonable comparison of the bur-
den of interval cancers across mammography screening
programs by comparing the ICR instead of the PICR. It
does, of course, not explain other, more in-depth, issues
concerning the burden of interval cancers such as differ-
ence in tumor size or stage between screen detected and
interval cancers.
Strengths & weaknesses
This study includes data from many mammography
screening programs throughout Western Europe, which
support the potential for use of this simple measure in
different settings. As pointed out by the very limited
number of studies available for this study, only a few
programs actually estimate PICR and thereby check if
the sensitivity follows the European guidelines. It is
much simpler to calculate ICR, and we therefore believe
that reporting of the program sensitivity would be much
more common if the gold standard was to use ICR.
Using the ICR as a performance indicator instead of the
PICR will facilitate comparisons between screening
programs.
Some of the centers included in this study allow for
early recall. We adopted the method from Törnberg
et al. 2010 and calculated cases detected at early recall
as screen detected cancers. Whether cases detected at
early recall are counted as screen detected cancers or
interval cancers, will have a very minor impact on our
study as we are comparing PICR = IC/(expected back-
ground incidence) to ICR = IC/(IC + SD), which is equi-
valent to comparing 1/(expected background incidence)
to 1/(IC + SD).
It is a strength that the ICR is not affected by uncer-
tainties in the estimates of background incidence, and
the ICR is therefore not subject to over-estimation of
the burden of interval cancers caused by an under-
estimated background incidence. It is, however, a weak-
ness that, unlike for the PICR, the ICR is affected by
overdiagnosis, since overdiagnosis will increase the num-
ber of screen-detected cases. As the number of screen
detected breast cancers is included in the denominator
in the calculation of the ICR, this measure could be
sensitive to overdiagnosis at screening. Reliable data on
overdiagnosis have been reported from the programmes
in Denmark and Florence, finding overdiagnosis to ac-
count for 1-5% of all incident breast cancers [13,14].
Larger estimates of overdiagnosis have been reported in
the literature, but they mainly reflect that the estimatesare not adequately adjusted [15]. An overdiagnosis of 1-
5% would change the size of ICR only marginally, where-
fore it would not be a major concern in the interpretation
of ICRs. Comparing programs with huge differences in
overdiagnosis will still favor the program with many
overdiagnosed cases. It is a trade-off when choosing one
measure instead of the other, but we argue that there are
fewer uncertainties involved in calculating the ICR than
in calculating the PICR.
Conclusion
In this study we proposed and validated the ICR as an
alternative measure for the burden of interval cancers.
The proposed measure seems to capture the burden of
interval cancers just as well or better than the traditional
PICR, as there is no need for estimations of background
incidence. In order to further validate this proposed
measure, more studies are needed. It should be noted
that the measure of ICR should be seen in the context of
other short-term performance indicators, and hence
should not stand alone in the evaluation of screening
performance.
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